Confirmed 0 9 0 9 O
positive 10 18 10 18 O
test 19 23 19 23 O
results 24 31 24 31 O
for 32 35 32 35 O
human 36 41 36 41 B-chronic_disease
immunodeficiency 42 58 42 58 I-chronic_disease
virus 59 64 59 64 I-chronic_disease
( 65 66 65 66 I-chronic_disease
HIV 66 69 66 69 I-chronic_disease
) 69 70 69 70 I-chronic_disease

Current 0 7 71 78 O
or 8 10 79 81 O
prior 11 16 82 87 O
use 17 20 88 91 O
of 21 23 92 94 O
immunosuppressive 24 41 95 112 B-treatment
medication 42 52 113 123 I-treatment
within 53 59 124 130 O
14 60 62 131 133 B-upper_bound
days 63 67 134 138 I-upper_bound
prior 68 73 139 144 I-upper_bound
to 74 76 145 147 O
the 77 80 148 151 O
first 81 86 152 157 O
dose 87 91 158 162 O
( 92 93 163 164 O
with 93 97 164 168 O
certain 98 105 169 176 O
exceptions 106 116 177 187 O
) 116 117 187 188 O

For 0 3 189 192 O
Combination 4 15 193 204 B-treatment
therapy 16 23 205 212 I-treatment
, 23 24 212 213 O
participant 25 36 214 225 O
must 37 41 226 230 O
not 42 45 231 234 O
have 46 50 235 239 O
had 51 54 240 243 O
prior 55 60 244 249 O
exposure 61 69 250 258 O
to 70 72 259 261 O
Rovalpituzumab 73 87 262 276 B-treatment
Tesirine 88 96 277 285 I-treatment
or 97 99 286 288 O
a 100 101 289 290 O
pyrrolobenzodiazepine 102 123 291 312 B-treatment
( 124 125 313 314 I-treatment
PBD 125 128 314 317 I-treatment
) 128 129 317 318 I-treatment
based 130 135 319 324 O
drug 136 140 325 329 O

History 0 7 330 337 O
of 8 10 338 340 O
primary 11 18 341 348 O
immunodeficiency 19 35 349 365 B-chronic_disease
, 35 36 365 366 O
bone 37 41 367 371 B-treatment
marrow 42 48 372 378 I-treatment
transplantation 49 64 379 394 I-treatment
, 64 65 394 395 O
chronic 66 73 396 403 B-cancer
lymphocytic 74 85 404 415 I-cancer
leukemia 86 94 416 424 I-cancer
, 94 95 424 425 O
solid 96 101 426 431 B-treatment
organ 102 107 432 437 I-treatment
transplantation 108 123 438 453 I-treatment
, 123 124 453 454 O
or 125 127 455 457 O
previous 128 136 458 466 O
clinical 137 145 467 475 O
diagnosis 146 155 476 485 O
of 156 158 486 488 O
tuberculosis 159 171 489 501 B-chronic_disease

Participant 0 11 502 513 O
has 12 15 514 517 O
an 16 18 518 520 O
Eastern 19 26 521 528 B-clinical_variable
Cooperative 27 38 529 540 I-clinical_variable
Oncology 39 47 541 549 I-clinical_variable
Group 48 53 550 555 I-clinical_variable
( 54 55 556 557 I-clinical_variable
ECOG 55 59 557 561 I-clinical_variable
) 59 60 561 562 I-clinical_variable
Performance 61 72 563 574 I-clinical_variable
Status 73 79 575 581 I-clinical_variable
of 80 82 582 584 O
0 83 84 585 586 B-lower_bound
to 85 87 587 589 O
2 88 89 590 591 B-upper_bound
for 90 93 592 595 O
Monotherapy 94 105 596 607 B-treatment
and 106 109 608 611 O
0 110 111 612 613 O
to 112 114 614 616 O
1 115 116 617 618 B-upper_bound
for 117 120 619 622 O
Combination 121 132 623 634 O

Participant 0 11 635 646 O
has 12 15 647 650 O
known 16 21 651 656 O
history 22 29 657 664 O
or 30 32 665 667 O
inflammatory 33 45 668 680 B-chronic_disease
bowel 46 51 681 686 I-chronic_disease
disease 52 59 687 694 I-chronic_disease
, 59 60 694 695 O
pneumonitis 61 72 696 707 B-chronic_disease
, 72 73 707 708 O
or 74 76 709 711 O
known 77 82 712 717 O
uncontrolled 83 95 718 730 B-cancer
metastases 96 106 731 741 I-cancer
to 107 109 742 744 O
the 110 113 745 748 O
central 114 121 749 756 O
nervous 122 129 757 764 O
system 130 136 765 771 O
( 137 138 772 773 O
CNS 138 141 773 776 O
) 141 142 776 777 O
( 143 144 778 779 O
with 144 148 779 783 O
certain 149 156 784 791 O
exceptions 157 167 792 802 O
) 167 168 802 803 O

Participant 0 11 804 815 O
has 12 15 816 819 O
received 16 24 820 828 O
anticancer 25 35 829 839 B-treatment
therapy 36 43 840 847 I-treatment
including 44 53 848 857 O
chemotherapy 54 66 858 870 B-treatment
, 66 67 870 871 O
immunotherapy 68 81 872 885 B-treatment
, 81 82 885 886 O
radiation 83 92 887 896 B-treatment
therapy 93 100 897 904 I-treatment
, 100 101 904 905 O
biologic 102 110 906 914 B-treatment
, 110 111 914 915 O
herbal 112 118 916 922 B-treatment
therapy 119 126 923 930 I-treatment
, 126 127 930 931 O
or 128 130 932 934 O
any 131 134 935 938 O
investigational 135 150 939 954 B-treatment
therapy 151 158 955 962 I-treatment
within 159 165 963 969 O
a 166 167 970 971 O
period 168 174 972 978 O
of 175 177 979 981 O
5 178 179 982 983 B-upper_bound
half 180 184 984 988 I-upper_bound
- 184 185 988 989 I-upper_bound
lives 185 190 989 994 I-upper_bound
, 190 191 994 995 O
prior 192 197 996 1001 O
to 198 200 1002 1004 O
the 201 204 1005 1008 O
first 205 210 1009 1014 O
dose 211 215 1015 1019 O
of 216 218 1020 1022 O
ABBV-181 219 227 1023 1031 B-treatment
or 228 230 1032 1034 O
Rovalpituzumab 231 245 1035 1049 B-treatment
Tesirine 246 254 1050 1058 I-treatment

Participant 0 11 1059 1070 O
has 12 15 1071 1074 O
unresolved 16 26 1075 1085 O
adverse 27 34 1086 1093 O
events 35 41 1094 1100 O
greater 42 49 1101 1108 O
than 50 54 1109 1113 O
grade 55 60 1114 1119 B-lower_bound
1 61 62 1120 1121 I-lower_bound
from 63 67 1122 1126 O
prior 68 73 1127 1132 B-treatment
anticancer 74 84 1133 1143 I-treatment
therapy 85 92 1144 1151 I-treatment
except 93 99 1152 1158 O
for 100 103 1159 1162 O
alopecia 104 112 1163 1171 B-chronic_disease

Participants 0 12 1172 1184 O
in 13 15 1185 1187 O
the 16 19 1188 1191 O
expansion 20 29 1192 1201 O
cohort 30 36 1202 1208 O
must 37 41 1209 1213 O
have 42 46 1214 1218 O
measurable 47 57 1219 1229 O
disease 58 65 1230 1237 O
per 66 69 1238 1241 O
RECIST 70 76 1242 1248 O
version 77 84 1249 1256 O
1.1 85 88 1257 1260 O
or 89 91 1261 1263 O
disease 92 99 1264 1271 O
evaluable 100 109 1272 1281 O
by 110 112 1282 1284 O
assessment 113 123 1285 1295 O
of 124 126 1296 1298 O
tumor 127 132 1299 1304 B-cancer
antigens 133 141 1305 1313 O

Participants 0 12 1314 1326 O
with 13 17 1327 1331 O
a 18 19 1332 1333 O
history 20 27 1334 1341 O
of 28 30 1342 1344 O
or 31 33 1345 1347 O
ongoing 34 41 1348 1355 O
interstitial 42 54 1356 1368 B-chronic_disease
lung 55 59 1369 1373 I-chronic_disease
disease 60 67 1374 1381 I-chronic_disease

Subjects 0 8 1382 1390 O
who 9 12 1391 1394 O
have 13 17 1395 1399 O
a 18 19 1400 1401 O
history 20 27 1402 1409 O
of 28 30 1410 1412 O
hepatitis 31 40 1413 1422 B-chronic_disease
B 41 42 1423 1424 I-chronic_disease
or 43 45 1425 1427 I-chronic_disease
C 46 47 1428 1429 I-chronic_disease
who 48 51 1430 1433 O
have 52 56 1434 1438 O
undetectable 57 69 1439 1451 O
HBV 70 73 1452 1455 B-chronic_disease
DNA 74 77 1456 1459 O
or 78 80 1460 1462 O
HCV 81 84 1463 1466 B-chronic_disease
RNA 85 88 1467 1470 O
are 89 92 1471 1474 O
anti 93 97 1475 1479 B-treatment
- 97 98 1479 1480 I-treatment
viral 98 103 1480 1485 I-treatment
therapy 104 111 1486 1493 I-treatment

participants 0 12 1494 1506 O
with 13 17 1507 1511 O
chronic 18 25 1512 1519 B-chronic_disease
or 26 28 1520 1522 I-chronic_disease
active 29 35 1523 1529 I-chronic_disease
hepatitis 36 45 1530 1539 I-chronic_disease
A 46 47 1540 1541 I-chronic_disease
, 47 48 1541 1542 I-chronic_disease
B 49 50 1543 1544 I-chronic_disease
or 51 53 1545 1547 I-chronic_disease
C 54 55 1548 1549 I-chronic_disease

the 0 3 1550 1553 O
participant 4 15 1554 1565 O
must 16 20 1566 1570 O
be 21 23 1571 1573 O
have 24 28 1574 1578 O
SCLC 29 33 1579 1583 B-cancer
with 34 38 1584 1588 O
progressive 39 50 1589 1600 O
disease 51 58 1601 1608 O
and 59 62 1609 1612 O
have 63 67 1613 1617 O
failed 68 74 1618 1624 O
platinum 75 83 1625 1633 O
containing 84 94 1634 1644 O
therapy 95 102 1645 1652 B-treatment
and 103 106 1653 1656 O
be 107 109 1657 1659 O
PD-1 110 114 1660 1664 O
/ 114 115 1664 1665 O
PD 115 117 1665 1667 O
- 117 118 1667 1668 O
L1 118 120 1668 1670 O
targeting 121 130 1671 1680 O
agent 131 136 1681 1686 O
na√Øve 137 142 1687 1692 O

